Invention Grant
- Patent Title: Bispecific antibodies against CEACAM5 and CD47
-
Application No.: US17554941Application Date: 2021-12-17
-
Publication No.: US11753481B2Publication Date: 2023-09-12
- Inventor: Vanessa Buatois , Dirk Hose , Anja Seckinger
- Applicant: LamKap Bio Beta AG
- Applicant Address: CH Schwyz Pfäffikon
- Assignee: LAMKAP BIO BETA LTD
- Current Assignee: LAMKAP BIO BETA LTD
- Current Assignee Address: CH Schwyz Pfäffikon
- Agency: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
- Priority: EP 215766 2020.12.18
- Main IPC: C07K16/46
- IPC: C07K16/46 ; C07K16/30 ; A61P35/00 ; C07K16/28 ; A61K39/00

Abstract:
The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.
Public/Granted literature
- US20220195067A1 BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 Public/Granted day:2022-06-23
Information query